Simparica Trio Chewable Tablets for Dogs >20–40 kg

Dose
The veterinary medicinal product should be administered at a dose of 1.2–2.4 mg/kg
of sarolaner, 0.024–0.048 mg/kg of moxidectin and 5–10 mg/kg of pyrantel in
accordance with the following table:
Bodyweight (kg)Tablet strength
48 mg/0.96 mg/200 mg
>20–40 kg1
To ensure a correct dosage, body weight should be determined as accurately as
possible.
Underdosing could result in ineffective use and may favour resistance development.
Method of administration
Tablets can be administered with or without food.
Simparica Trio tablets are palatable and readily consumed by the majority of dogs
when offered by the owner. If the tablet is not taken up voluntarily by the dog it can
also be given with food or directly into the mouth. The tablets should not be divided.
Treatment schedule:
The treatment schedule should be based on veterinary diagnosis, the local
epidemiological situation and/or the epidemiological situation of other areas the dog
has visited or is going to visit. If based on veterinarian opinion re-administration(s) of
the product is required, any subsequent administration(s) must follow the minimum 1-
month interval schedule.
The product should only be used in dogs when treatment of ticks / fleas / mites and
gastrointestinal nematodes is indicated at the same time. In the absence of the risk of
mixed co-infestation, a narrower spectrum parasiticide should be used.
Treatment of flea and tick infestations and gastrointestinal nematodes:
The veterinary medicinal product can be used as part of the seasonal treatment of
fleas and ticks (replacing treatment with a mono-active flea and tick product) in dogs
with diagnosed concurrent gastrointestinal nematode infections.
A single treatment is efficacious for the treatment of gastrointestinal nematodes.
After treatment of the nematode infections, further flea and tick treatment should be
continued with a mono-active product.
Prevention of heartworm disease and angiostrongylosis:
A single administration also prevents lungworm disease (by reducing the immature
adults (L5) of A. vasorum) and heartworm disease (D. immitis) for one month. When
the product replaces another lungworm or heartworm preventive product, the first
dose of the product should be given within a month of the last dose of the former
veterinary medicinal product. In endemic areas, dogs should receive lungworm
and/or heartworm preventive treatments at monthly intervals. It is recommended that
heartworm prevention treatment should be continued until at least 1 month after the
last exposure to mosquitoes.
Treatment of angiostrongylosis (caused by Angiostrongylus vasorum):
A single dose should be administered. A further veterinary examination 30 days after
treatment is recommended as some animals may require a second treatment. A
further assessment should then be carried out following the second treatment.
Continued monitoring should be performed as appropriate for each case.
Prevention of establishment of thelaziosis (adult Thelazia callipaeda eyeworm
infection):
Monthly administration of the product prevents establishment of infection with adult
Thelazia callipaeda eyeworm.
Treatment of demodicosis (caused by Demodex canis):
Administration of a single dose once monthly for two consecutive months is
efficacious and leads to a marked improvement of clinical signs. Treatment should be
continued until skin scrapings are negative on at least two consecutive occasions
one month apart. As demodicosis is a multifactorial disease, it is advisable to also
treat any contributing, underlying conditions appropriately.
Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis):
Administration of a single dose at monthly intervals for two consecutive months.
Further monthly administrations of the product may be required based on clinical
assessment and skin scrapings.